6 April 2021 - NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anti-coagulation of the direct factor Xa inhibitors apixaban or rivaroxaban in adults who experience a life-threatening or uncontrolled bleed in the gastro-intestinal tract.

Until now, there has been no licensed therapy to reverse factor Xa-associated major bleeds when treated with apixaban or rivaroxaban, which are increasingly used for the prevention and treatment of thrombotic events, such as deep vein thrombosis and pulmonary embolism, or if a patient is at high risk of a stroke due to atrial fibrillation.

Read Pharma Times article